ATE439443T1 - NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON - Google Patents

NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON

Info

Publication number
ATE439443T1
ATE439443T1 AT06752809T AT06752809T ATE439443T1 AT E439443 T1 ATE439443 T1 AT E439443T1 AT 06752809 T AT06752809 T AT 06752809T AT 06752809 T AT06752809 T AT 06752809T AT E439443 T1 ATE439443 T1 AT E439443T1
Authority
AT
Austria
Prior art keywords
peptide derivatives
new
binding protein
disease
disclosed
Prior art date
Application number
AT06752809T
Other languages
English (en)
Inventor
Balu Chakravarthy
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Application granted granted Critical
Publication of ATE439443T1 publication Critical patent/ATE439443T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06752809T 2005-06-17 2006-06-16 NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON ATE439443T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69124805P 2005-06-17 2005-06-17
PCT/CA2006/000990 WO2006133566A1 (en) 2005-06-17 2006-06-16 NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF

Publications (1)

Publication Number Publication Date
ATE439443T1 true ATE439443T1 (de) 2009-08-15

Family

ID=37531931

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06752809T ATE439443T1 (de) 2005-06-17 2006-06-16 NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON

Country Status (7)

Country Link
US (1) US8323925B2 (de)
EP (1) EP1896588B1 (de)
AT (1) ATE439443T1 (de)
CA (1) CA2611054C (de)
DE (1) DE602006008460D1 (de)
ES (1) ES2329511T3 (de)
WO (1) WO2006133566A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0803912D0 (en) * 2008-02-29 2008-05-07 Univ Bristol Novel Uses of VEGFxxxb
GB0804496D0 (en) 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
WO2017083700A1 (en) * 2015-11-13 2017-05-18 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
AU2018212860A1 (en) * 2017-01-30 2019-08-15 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
BR112022009273A2 (pt) * 2019-11-15 2022-10-04 Univ Tennessee Res Found Imunoglobulinas modificadas para direcionar depósitos amiloides
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
US20240002437A1 (en) * 2020-10-30 2024-01-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods of treating inflammatory lung diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
AU2001263006A1 (en) * 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2002304814A1 (en) 2001-03-14 2002-11-05 Hybrigenics Protein-protein interactions in adipocytes
AU2003207628A1 (en) * 2002-01-18 2003-09-02 Incyte Corporation Structural and cytoskeleton-associated proteins

Also Published As

Publication number Publication date
ES2329511T3 (es) 2009-11-26
DE602006008460D1 (de) 2009-09-24
US8323925B2 (en) 2012-12-04
CA2611054A1 (en) 2006-12-21
WO2006133566A1 (en) 2006-12-21
CA2611054C (en) 2017-05-09
EP1896588A1 (de) 2008-03-12
US20110300141A1 (en) 2011-12-08
EP1896588A4 (de) 2008-08-20
EP1896588B1 (de) 2009-08-12

Similar Documents

Publication Publication Date Title
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
WO2005123048A3 (en) Screening methods using c-abl, fyn and syk in combination with tau protein
WO2006082406A3 (en) Human antibodies and proteins
BRPI0911482A2 (pt) Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer
NO20064059L (no) Albumin fusjonsproteiner
TNSN08064A1 (en) Albumin fusion proteins
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
DE60032486D1 (de) Prion protein peptide und deren verwendung
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2007044323A3 (en) Fusion proteins for blood-brain barrier delivery
MX2009002816A (es) Proteinas de fusion de albumina.
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
AR069860A1 (es) Metodo para purificar un anticuerpo cd20
EA201100072A1 (ru) Новые композиции и способы
WO2008034016A3 (en) Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
EA201100071A1 (ru) Новые композиции и способы
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties